In a bipartisan spending agreement that was largely negotiated behind closed doors, Congress included a policy change with ...
The closer we get to 2028, the more likely it is that the U.S. may settle for short-term solutions that do not meaningfully ...
This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...
When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...
If New York legislators have questions about the efficacy of the 340B Drug Pricing Program, they should look closely at a ...
That bipartisan effort proved that when elected officials put patients first, we can expand access to care and strengthen our ...
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...
The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...
The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results